These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 20502723)

  • 1. Ustekinumab for the treatment of psoriasis: review of three multicenter clinical trials.
    Farhi D
    Drugs Today (Barc); 2010 Apr; 46(4):259-64. PubMed ID: 20502723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
    Woolacott N; Hawkins N; Mason A; Kainth A; Khadjesari Z; Vergel YB; Misso K; Light K; Chalmers R; Sculpher M; Riemsma R
    Health Technol Assess; 2006 Nov; 10(46):1-233, i-iv. PubMed ID: 17083854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.
    Griffiths CE; Strober BE; van de Kerkhof P; Ho V; Fidelus-Gort R; Yeilding N; Guzzo C; Xia Y; Zhou B; Li S; Dooley LT; Goldstein NH; Menter A;
    N Engl J Med; 2010 Jan; 362(2):118-28. PubMed ID: 20071701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of ustekinumab and etanercept for the treatment of psoriasis.
    Uhlenhake EE; Feldman SR
    Expert Opin Biol Ther; 2010 Jul; 10(7):1105-12. PubMed ID: 20446825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ustekinumab: new drug. Suspicion of carcinogenicity: too great a risk for psoriasis patients.
    Prescrire Int; 2009 Oct; 18(103):202-4. PubMed ID: 19882785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials.
    Reich K; Burden AD; Eaton JN; Hawkins NS
    Br J Dermatol; 2012 Jan; 166(1):179-88. PubMed ID: 21910698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials.
    Lebwohl M; Leonardi C; Griffiths CE; Prinz JC; Szapary PO; Yeilding N; Guzzo C; Li S; Hsu MC; Strober B
    J Am Acad Dermatol; 2012 May; 66(5):731-41. PubMed ID: 21930328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ACCEPT study: ustekinumab versus etanercept in moderate-to-severe psoriasis patients.
    Young MS; Horn EJ; Cather JC
    Expert Rev Clin Immunol; 2011 Jan; 7(1):9-13. PubMed ID: 21162644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psoriasis: Is ustekinumab superior to etanercept for psoriasis?
    Kuhn A; Luger TA
    Nat Rev Rheumatol; 2010 Sep; 6(9):500-1. PubMed ID: 20808304
    [No Abstract]   [Full Text] [Related]  

  • 10. Ustekinumab for the treatment of psoriasis.
    Laws PM; Warren RB
    Expert Rev Clin Immunol; 2011 Mar; 7(2):155-64. PubMed ID: 21426253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials.
    Brimhall AK; King LN; Licciardone JC; Jacobe H; Menter A
    Br J Dermatol; 2008 Aug; 159(2):274-85. PubMed ID: 18547300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost utility analysis based on a head-to-head Phase 3 trial comparing ustekinumab and etanercept in patients with moderate-to-severe plaque psoriasis: a Canadian perspective.
    Pan F; Brazier NC; Shear NH; Jivraj F; Schenkel B; Brown R
    Value Health; 2011; 14(5):652-6. PubMed ID: 21839402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost per responder analysis of ustekinumab and etanercept for moderate to severe plaque psoriasis.
    Martin S; Feldman SR; Augustin M; Szapary P; Schenkel B
    J Dermatolog Treat; 2011 Jun; 22(3):138-43. PubMed ID: 21254886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis.
    Strober BE; Crowley JJ; Yamauchi PS; Olds M; Williams DA
    Br J Dermatol; 2011 Sep; 165(3):661-8. PubMed ID: 21574984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis.
    Weinberg JM
    Clin Ther; 2003 Oct; 25(10):2487-505. PubMed ID: 14667953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept.
    Van Lümig PP; Lecluse LL; Driessen RJ; Spuls PI; Boezeman JB; van de Kerkhof PC; De Jong EM
    Br J Dermatol; 2010 Oct; 163(4):838-46. PubMed ID: 20649798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological treatments for moderate-to-severe psoriasis: indirect comparison.
    Galván-Banqueri M; Marín Gil R; Santos Ramos B; Bautista Paloma FJ
    J Clin Pharm Ther; 2013 Apr; 38(2):121-30. PubMed ID: 23442134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials.
    Ryan C; Leonardi CL; Krueger JG; Kimball AB; Strober BE; Gordon KB; Langley RG; de Lemos JA; Daoud Y; Blankenship D; Kazi S; Kaplan DH; Friedewald VE; Menter A
    JAMA; 2011 Aug; 306(8):864-71. PubMed ID: 21862748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secukinumab in plaque psoriasis--results of two phase 3 trials.
    Langley RG; Elewski BE; Lebwohl M; Reich K; Griffiths CE; Papp K; Puig L; Nakagawa H; Spelman L; Sigurgeirsson B; Rivas E; Tsai TF; Wasel N; Tyring S; Salko T; Hampele I; Notter M; Karpov A; Helou S; Papavassilis C; ;
    N Engl J Med; 2014 Jul; 371(4):326-38. PubMed ID: 25007392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative efficacy of biological treatments for moderate-to-severe psoriasis: a network meta-analysis adjusting for cross-trial differences in reference arm response.
    Signorovitch JE; Betts KA; Yan YS; LeReun C; Sundaram M; Wu EQ; Mulani P
    Br J Dermatol; 2015 Feb; 172(2):504-12. PubMed ID: 25288183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.